Effectiveness of intranasal esketamine in the treatment of patients with treatment-resistant depression: an observational study based on data collected in a Spravato treatment program at the Institute of Living, Hartford, CT

Key Points

• Intranasal esketamine improves symptoms in treatment-resistant depression, showing promise as an effective intervention.
• The study reports a significant reduction in depressive scores after treatment with esketamine over several weeks.
• Observational study for assessing outcomes of the Spravato treatment program at the Institute of Living in Hartford.
• The findings suggest further exploration into esketamine's role is warranted, as it could offer hope where other treatments fail.